ciprofloxacin has been researched along with Connective Tissue Diseases in 6 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous ciprofloxacin at a daily dosage of 400 mg divided in two doses was administered to 19 patients with severe infections caused by ciprofloxacin-susceptible bacteria." | 1.28 | Intravenous ciprofloxacin for the treatment of severe infections. ( Baiocchi, P; Brandimarte, C; Gelfusa, V; Santini, C; Serra, P; Tarasi, A; Venditti, M, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Huruba, M | 1 |
| Farcas, A | 1 |
| Leucuta, DC | 1 |
| Bucsa, C | 1 |
| Sipos, M | 1 |
| Mogosan, C | 1 |
| Stahlmann, R | 1 |
| Santini, C | 1 |
| Baiocchi, P | 1 |
| Venditti, M | 1 |
| Gelfusa, V | 1 |
| Tarasi, A | 1 |
| Brandimarte, C | 1 |
| Serra, P | 1 |
| Westmoreland, D | 1 |
| Woodwards, RT | 1 |
| Holden, PE | 1 |
| James, PA | 1 |
| Thadepalli, H | 1 |
| Mathai, D | 1 |
| Chuah, SK | 1 |
| Bansal, MB | 1 |
| Scully, BE | 1 |
| Neu, HC | 1 |
| Parry, MF | 1 |
| Mandell, W | 1 |
1 trial available for ciprofloxacin and Connective Tissue Diseases
| Article | Year |
|---|---|
Ciprofloxacin versus ceftazidime in skin and soft tissue infections.
Topics: Administration, Oral; Bacterial Infections; Ceftazidime; Ciprofloxacin; Clinical Trials as Topic; Co | 1989 |
5 other studies available for ciprofloxacin and Connective Tissue Diseases
| Article | Year |
|---|---|
A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Adverse Drug Reaction Reporting Systems; Arthralgia; Cip | 2021 |
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |
Intravenous ciprofloxacin for the treatment of severe infections.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Connective Tissue Diseases; Female; Humans; Inject | 1991 |
Soft tissue abscess caused by Mycobacterium fortuitum.
Topics: Abscess; Adult; Cefoxitin; Ciprofloxacin; Connective Tissue Diseases; Humans; Male; Mycobacterium In | 1990 |
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary | 1986 |